NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Imunon, Inc. (IMNN) Stock Analysis

Imunon, Inc. (IMNN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMNN

$1.58

+$0.02 (+1.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMNN with… →

IMNN Key Statistics

As of Sep 4, 2026
Trading
Open
$1.56
Previous Close
$1.56
Day's Range
1.54–1.58
52-Week Range
1.47–6.03
Volume
34.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.98
Valuation
Market Cap
$8.87M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
5.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.96
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$14.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.61M
1-Year Return
−72.38%
Dividend and dates
Avg Volume
125.06K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMNN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−58.53%
2025−69.25%
2024+39.71%
2023−49.63%
2022−83.33%
2021−23.94%
2020−58.48%
2019+21.28%
2018−47.39%
2017−36.19%
2016 (partial year)−76.00%

As of September 4, 2026.

IMNN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$14.50M—
2024$0.00−$18.62M—
2023$0.00−$19.51M—
2022$500.00K−$35.90M−7179.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$14.65M−$14.50M—
2024$0.00—−$19.13M−$18.62M—
2023$0.00—−$21.03M−$19.51M—
2022$500.00K—−$24.92M−$35.90M−7179.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMNN Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMNNBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Imunon, Inc. (IMNN) carries a market capitalisation of $8.87M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 20 employees.

IMNN last closed at $1.58 on September 4, 2026. That is +$0.02 (+1.28%) against the previous close. Over the past 52 weeks the price has ranged from $1.47 to $6.03. The latest close sits 7.48% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $14.50M. Profit margin runs at 0%. Trailing earnings per share are −2.96.

Across the 4 fiscal years on file, revenue moves from $500.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 5.03.

The reported beta is 1.98. Annualized volatility over the trailing 10 years is 162.29%. The trailing one-year price return is −72.38%. Across 10 years the annualized return works out at −53.42%.

Growth & Income

No dividend is on file for IMNN.

So far in 2026 the price is −58.53%. The strongest complete calendar year on file is 2024 at +39.71%; the weakest is 2022 at −83.33%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Imunon, Inc. (IMNN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Imunon, Inc. IMNN $8.87M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Imunon, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Imunon, Inc.

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Visit website →